TY - JOUR
T1 - Eff ectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021
AU - Glatman-Freedman, Aharona
AU - Hershkovitz, Yael
AU - Kaufman, Zalman
AU - Dichtiar, Rita
AU - Keinan-Boker, Lital
AU - Bromberg, Michal
N1 - Publisher Copyright:
© 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.
AB - In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.
UR - http://www.scopus.com/inward/record.url?scp=85117942942&partnerID=8YFLogxK
U2 - 10.3201/eid2711.211886
DO - 10.3201/eid2711.211886
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34570694
AN - SCOPUS:85117942942
SN - 1080-6040
VL - 27
SP - 2919
EP - 2922
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 11
ER -
